In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Translational Center Should “Raise All Boats,” BIO Says

You may also be interested in...



NIH Translational Science Center Gets Expanded Powers In Cures Bill

When NCATS was created, industry was wary of allowing Phase III trials; now sponsors embrace it.

NIH’s Translational Science Center Could See Budget Trimmed

Republicans on appropriations subcommittee again seem concerned about whether NCATS will trample industry toes, which could lead to a more tightened focus for the new NIH center’s funding in the upcoming bill.

BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval

While it would not grab as much attention as creating a whole new approval pathway, BIO believes tinkering with accelerated approval to give the regulations more clarity and increase its use still could generate the change it wants at FDA.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel